|Bid||240.69 x 900|
|Ask||0.00 x 1000|
|Day's Range||299.51 - 307.34|
|52 Week Range||170.31 - 314.96|
|PE Ratio (TTM)||79.14|
|Earnings Date||Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||288.94|
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
To get a better sense of the sector, Jim Cramer looked at the charts in his "Off the Charts" segment of Mad Money Tuesday night with guest and colleague Bob Lang, founder of ExplosiveOptions.net and a contributor to TheStreet's Trifecta Stocks newsletter. Lang likes the recent pattern of higher highs and higher lows. Gilead's Moving Average Convergence Divergence or MACD line, which helps technician's detect changes in a stock's trajectory before they happen, made a strong buy signal a few weeks ago, with the black line crossing above the red one.
CNBC's Jim Cramer and technician Bob Lang inspect the charts to see if big-cap biotechnology stocks like Gilead and Celgene could have more room to run. Given recent positive trends in key technical indicators, Lang says these stocks could be prime for a rally. CNBC's Jim Cramer was somewhat surprised to see the biotechnology sector bounce back in 2018 after months of weakness.
Johnson & Johnson's (JNJ) phase III CREDENCE study evaluating the efficacy and safety of its diabetes drug Invokana is being stopped early based on positive pre-specified efficacy data.
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
Sometimes it becomes difficult to measure the efficiency level of a company. Inventory Turnover: The ratio of 12-month cost of goods sold (COGS) to a four-quarter average inventory is considered one of the most popular efficiency ratios. While a high value indicates that the company has a relatively low level of inventory compared to COGS, a low value shows that the company is facing declining sales, which has resulted in excess inventory.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...
Aptose Biosciences (APTO) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
Illumina, Inc. today announced that it will issue results for second quarter 2018 following the close of market on Monday, July 30, 2018.
According to Boston Scientific’s (BSX) estimates, the market opportunity for its neuromodulation portfolio grew ~14% YoY (year-over-year) in 2017 to ~$2.5 billion. The company expects the market to grow at a compound annual rate of 10%–15% between 2017 and 2020.
Strong growth in consumables revenue is keeping Wall Street happy as it awaits the continued rollout of the latest gene-sequencing machine.
Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting ILMN. Over the last one-month, outflows of investor capital in ETFs holding ILMN totaled $1.06 billion.
Here we discuss about how Genomics creates opportunities in MedTech for investors who are keen on putting money in the healthcare space.
In this daily bar chart of ILMN, below, we can see that prices are in an uptrend above the rising 50-day and the bullish 200-day moving average lines. The On-Balance-Volume (OBV) line has been moving higher the past twelve months telling us that buyers of ILMN have been more aggressive. The Moving Average Convergence Divergence (MACD) oscillator just turned down to a take profits sell signal but remains above the zero line.